Characterisation and outcome of RAC1 mutated melanoma
Georg Lodde(Essen University Hospital), Klaus Griewank(Düsseldorf University Hospital), Jochen Utikal(German Cancer Research Center), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Lea Jessica Albrecht(Essen University Hospital), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Wolfgang Galetzka(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Jan‐Malte Placke(Düsseldorf University Hospital), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Alpaslan Tasdogan(Düsseldorf University Hospital), Elisabeth Livingstone(German Cancer Research Center), Antje Sucker(German Cancer Research Center), Philipp Jansen(German Cancer Research Center), Selma Ugurel(Klinikum Bielefeld), Lisa Zimmer(The University of Sydney), Anne Zaremba(National Center for Tumor Diseases), Jürgen C. Becker(Düsseldorf University Hospital), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Bernd Kowall(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Eva Hadaschik(West German Heart and Vascular Center Essen), Jens Ulrich, Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k